IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature

• Publication date

  2012-07-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature11323PMID 22763442PMCID PMC4005896
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Summary and discussion of : “ Controlling the False Discovery Rate : A Practical and Powerful Approach to Multiple Testing

  2014cited by this paper
• Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia

  2012cited by this paper
• Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.

  2011cited by this paper
• Self-renewal related signaling in myeloid leukemia stem cells

  2011cited by this paper
• Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

  2011cited by this paper
• Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications

  2011cited by this paper
• Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases

  2011cited by this paper
• A novel tumor suppressor function for the Notch pathway in myeloid leukemia

  2011cited by this paper
• Faculty Opinions recommendation of A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.

  2011cited by this paper
• Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• The hematopoietic stem cell niche: Low in oxygen but a nice place to be

  2010cited by this paper
• The UCSC Genome Browser database: update 2011

  2010cited by this paper
• Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

  2010cited by this paper
• Complex and Context Dependent Regulation of Hematopoiesis by TGF‐β Superfamily Signaling

  2009cited by this paper
• The OP9-DL1 system: generation of T-lymphocytes from embryonic or hematopoietic stem cells in vitro.

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

  2009cited by this paper
• The UCSC Genome Browser database: update 2010

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects

  2008cited by this paper
• Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy

  2008cited by this paper
• lumi: a pipeline for processing Illumina microarray

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.

  2007cited by this paper
• Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells

  2006cited by this paper
• Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry.

  2006cited by this paper
• Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis

  2005cited by this paper
• Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments

  2004cited by this paper
• Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential.

  2003cited by this paper
• Transgenic mice with hematopoietic and lymphoid specific expression of Cre

  2003cited by this paper
• Statistical significance for genomewide studies

  2003cited by this paper
• THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY

  2001cited by this paper
• Conditional gene targeting in macrophages and granulocytes using LysMcre mice

  1999cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper

• ZFTA-RELA ependymomas make itaconate to epigenetically drive fusion expression.

  2026cites this paper
• Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition

  2025cites this paper
• Mutant IDH silences GSX2 to reprogram neural progenitor cell fate and promote gliomagenesis

  2025cites this paper
• Programmable Argonaute-mediated single-nucleotide variant sequencing of cell-free DNA for multi-cancer early detection

  2025cites this paper
• Direct genetic transformation bypasses tumor-associated DNA methylation alterations

  2025cites this paper
• Development of D2HG biosensors inspired by the molecular mechanism of D2HG regulation of DhdR.

  2025cites this paper
• Recent Developments in Differentiation Therapy of Acute Myeloid Leukemia

  2025cites this paper
• Metabolic Reprogramming and Adaption in Breast Cancer Progression and Metastasis.

  2025cites this paper
• Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations.

  2025cites this paper
• Ultra-Fast Intraoperative IDH-Mutation Analysis Enables Rapid Stratification and Therapy Planning in Diffuse Gliomas

  2025cites this paper
• Clonal hematopoiesis: linking hematopoietic stem cell aging with age-related diseases

  2025cites this paper
• Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas.

  2025cites this paper
• [Metabolism and therapy in acute myeloid leukemia with isocitrate dehydrogenase 1/2 mutations].

  2025cites this paper
• Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.

  2025cites this paper
• Deciphering enemy tactics – the narrow path to an optimal anti-cancer strategy targeting the Warburg effect

  2025cites this paper
• Mutant IDH1 cooperates with NPM1c or FLT3ITD to drive distinct myeloid diseases and molecular outcomes

  2025cites this paper
• IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies

  2025cites this paper
• CAR-T cell therapy for cancer: current challenges and future directions

  2025cites this paper
• Contributions of transcriptional noise to leukaemia evolution: KAT2A as a case-study

  2024cites this paper
• IDH inhibition in gliomas: from preclinical models to clinical trials

  2024cites this paper
• Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.

  2024cites this paper
• The IDH1-R132H mutation aggravates cisplatin-induced acute kidney injury by promoting ferroptosis through disrupting NDUFA1 and FSP1 interaction

  2024cites this paper
• Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer

  2024cites this paper
• The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs)

  2024cites this paper
• IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma

  2024cites this paper
• Targeting the IDH1R132H mutation in gliomas by CRISPR/Cas precision base editing

  2024cites this paper
• Overlapping Stromal Alterations in Myeloid and Lymphoid Neoplasms

  2024cites this paper
• Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.

  2024cites this paper
• Immunoediting in acute myeloid leukemia: Reappraising T cell exhaustion and the aberrant antigen processing machinery in leukemogenesis

  2024cites this paper
• Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies.

  2024cites this paper
• Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors

  2024cites this paper
• Metabolite regulation of epigenetics in cancer.

  2024cites this paper
• Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxyglutarate in Cancer.

  2024cites this paper
• Rodent models of tumours of the central nervous system

  2024cites this paper
• Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma

  2023cites this paper
• Transgenerational Epigenetic DNA Methylation Editing and Human Disease

  2023cites this paper
• N6-Methyladenosine RNA Modification in Normal and Malignant Hematopoiesis.

  2023cites this paper
• HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma

  2023cites this paper
• Mutant IDH in Gliomas: Role in Cancer and Treatment Options

  2023cites this paper
• Research Progress in the Relationship and Role of IDH1/2 Gene Mutation and Acute My-eloid Leukemia

  2023cites this paper
• Approaches to Study Tumor Metabolism in Mice

  2023cites this paper
• The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

  2023cites this paper
• Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes

  2023cites this paper
• D-2-hydroxyglutarate dehydrogenase governs adult neural stem cell activation and promotes histone acetylation via ATP-citrate lyase.

  2023cites this paper
• PRMT1 driven PTX3 regulates ferritinophagy in glioma

  2023cites this paper
• (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers.

  2023cites this paper
• Ivosidenib in acute myeloid leukemia

  2023cites this paper
• Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma

  2023cites this paper
• Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes

  2023cites this paper
• Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression

  2023cites this paper
• Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation

  2023cites this paper
• HDAC6 deacetylates IDH1 to promote the homeostasis of hematopoietic stem and progenitor cells

  2023cites this paper
• Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.

  2023cites this paper
• CpG Island Methylator Phenotype—A Hope for the Future or a Road to Nowhere?

  2022cites this paper
• Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.

  2022cites this paper
• A non-coding single nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation

  2022cites this paper
• Interferon-Stimulated Exonuclease Gene 20 is A Prognosis and Predictive Biomarker and Correlated with Macrophages M2 Polarization in Glioblastoma: A Pan-Cancer Analysis

  2022cites this paper
• Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair

  2022cites this paper
• Lessons from mouse models of MPN.

  2022cites this paper
• Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets.

  2022cites this paper
• Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia

  2022cites this paper
• Mutant IDH1 attenuates hepatic lipogenesis through PTEN dependent pathway.

  2022cites this paper
• Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis.

  2022cites this paper
• Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

  2022cites this paper
• Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities

  2022cites this paper
• The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications

  2022cites this paper
• De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma

  2022cites this paper
• Pathogenic Mechanisms in Acute Myeloid Leukemia

  2022cites this paper
• Glioblastoma Treatment: State-of-the-Art and Future Perspectives

  2022cites this paper
• A murine model for human early/immature T-cell precursor acute lymphoblastic leukemia (EITP ALL)

  2022cites this paper
• Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells

  2022cites this paper
• Epigenetic Maintenance Strategies after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.

  2022cites this paper
• Exosome-based strategies for diagnosis and therapy of glioma cancer

  2022cites this paper
• Targeting STAT5 signaling overcomes resistance to IDH inhibitors in acute myeloid leukemia through suppression of stemness.

  2022cites this paper
• 2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies

  2022cites this paper
• Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma

  2022cites this paper
• Dissecting TET2 Regulatory Networks in Blood Differentiation and Cancer

  2022cites this paper
• Biology of IDH mutant cholangiocarcinoma

  2022cites this paper
• Modulation of DNA/RNA Methylation Signaling Mediating Metabolic Homeostasis in Cancer.

  2022cites this paper
• A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation

  2022cites this paper
• IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy

  2021cites this paper
• Defining the landscape of metabolic dysregulations in cancer metastasis

  2021cites this paper
• Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma

  2021cites this paper
• Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells

  2021cites this paper
• Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia

  2021cites this paper
• Post-translational modifications on mitochondrial metabolic enzymes in cancer.

  2021cites this paper
• Alternative Lengthening of Telomeres: Lessons to Be Learned from Telomeric DNA Double-Strand Break Repair

  2021cites this paper
• Additional mutations in IDH1/2‐mutated patients with acute myeloid leukemia

  2021cites this paper
• DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model

  2021cites this paper
• The implications of IDH mutations for cancer development and therapy

  2021cites this paper
• Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL

  2021cites this paper
• Epigenetic dysregulation in myeloid malignancies.

  2021cites this paper
• Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours.

  2021cites this paper
• Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.

  2021cites this paper
• HnRNPA1 ISOFORM BRING DIVERSITY IN GLIOMA CELL SURVIVAL

  2021cites this paper
• Basic Research

  2021cites this paper
• Metabolomics of Glioma.

  2021cites this paper
• The Potential Equivalents of TET2 Mutations

  2021cites this paper
• DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA

  2021cites this paper
• Epigenetic Regulation of Genomic Stability by Vitamin C

  2021cites this paper